Echovirus for treatment of tumors
AssigneesXiamen University, Yang Sheng Tang Company, Ltd.
InventorsTong Cheng, Wei Wang, Junkai Wan, Longfa Xu, Xiangzhong Ye, Jun Zhang, Ningshao Xia
Life of this patent
Estimating the term…
Abstract
Provided are use of an Echovirus 25 (ECHO25) or a modified form thereof, or a nucleic acid molecule comprising a genomic sequence or cDNA sequence of the ECHO25 or a modified form thereof, or a complementary sequence of the genomic sequence or cDNA sequence, in treatment of a tumor in a subject, and in the manufacture of a medicament for treatment a tumor in a subject.
Claims18
A method of treating a tumor, the method comprising administering, to a subject in need thereof, an effective amount of a modified Echovirus 25 (ECHO25) or a medicament comprising the modified ECHO25,
- wherein as compared to a genome of a wild-type ECHO25, a genome of the modified ECHO25 has an insertion of one or more exogenous nucleic acids, and
- wherein the one or more exogenous nucleic acids are selected from the group consisting of a nucleic acid sequence encoding a cytokine, a nucleic acid sequence encoding an antitumor protein or polypeptide, and a target sequence of microRNA.
A modified ECHO25, comprising:
- a substitution of an internal ribosome entry site (IRES) sequence in a 5′ untranslated region (5′UTR) with an internal ribosome entry site sequence of human rhinovirus 2 (HRV2) as compared to a wild-type ECHO25, and
- an exogenous nucleic acid which is selected from the group consisting of a nucleic acid sequence encoding a cytokine, a nucleic acid sequence encoding an antitumor protein or polypeptide, and a target sequence of microRNA.
A method of treating a tumor, the method comprising administering, to a subject in need thereof, an effective amount of an isolated nucleic acid molecule comprising a genomic sequence or a cDNA sequence of a modified ECHO25, or a medicament comprising the isolated nucleic acid molecule,
- wherein as compared to a genome of a wild-type ECHO25, a genome of the modified ECHO25 has an insertion of one or more exogenous nucleic acids, and
- wherein the one or more exogenous nucleic acids are selected from the group consisting of a nucleic acid sequence encoding a cytokine, a nucleic acid sequence encoding an antitumor protein or polypeptide, and a target sequence of microRNA.
Dependencies are inferred from the claim text.